Last updated on November 2018

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

Brief description of study

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

Detailed Study Description

Fifteen subjects with moderate to severe AD will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). Biopsy samples from AD subjects and surgical discard samples will undergo molecular profiling. Skin swabs and stool samples will be collected and banked for future analysis. The reason to treat patients for 52 weeks is to have the ability to correlate early molecular events with clinical outcomes at week 52.

Clinical Study Identifier: NCT03293030

Contact Investigators or Research Sites near you

Start Over

Wilson Liao, MD

UCSF Psoriasis and Skin Treatment Center
San Francisco, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.